IO BiO Sciences Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$550K
- Investors
-
1
IO BiO Sciences General Information
Description
Developer of genetic cell modification technologies designed for therapeutic and biomanufacturing purposes. The company's platform incorporates a proprietary system allowing plug-and-play genetic engineering of mammalian cell lines, supports the creation of off-the-shelf natural killer cell therapies derived from pluripotent stem cells, applies virus-free electroporation methods, integrates scalable biomanufacturing of proteins and viral vectors, and provides flexible product development pathways, enabling the biotechnology and pharmaceutical markets to accelerate cancer therapy innovation, reduce production costs, expand licensing opportunities, and improve accessibility of advanced medicinal products through efficient and adaptable manufacturing systems.
Contact Information
Website
www.iobiosciences.comCorporate Office
- 3805 Old Easton Road
- Doylestown, PA 18902
- United States
Corporate Office
- 3805 Old Easton Road
- Doylestown, PA 18902
- United States
IO BiO Sciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC | 08-Oct-2020 | $550K | Completed | Pre-Clinical Trials | ||
| 4. Early Stage VC | 14-Feb-2020 | Completed | Pre-Clinical Trials | |||
| 3. Angel (individual) | Completed | Pre-Clinical Trials | ||||
| 2. Early Stage VC | 04-Jan-2019 | $250K | $945K | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 29-Mar-2018 | $695K | $695K | Completed | Pre-Clinical Trials |
IO BiO Sciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
IO BiO Sciences Patents
IO BiO Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4133086-A1 | Nucleic acid constructs comprising gene editing multi-sites | Pending | 07-Apr-2020 | ||
| EP-4133086-A4 | Nucleic acid constructs comprising gene editing multi-sites | Pending | 07-Apr-2020 | ||
| US-20240026350-A1 | Nucleic acid constructs comprising gene editing multi-sites | Pending | 07-Apr-2020 | ||
| WO-2021207401-A1 | Nucleic acid constructs comprising gene editing multi-sites | Inactive | 07-Apr-2020 | ||
| EP-3843790-A1 | Nucleic acid constructs comprising gene editing multi-sites and uses thereof | Inactive | 29-Aug-2018 | C12N15/11 |
IO BiO Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
IO BiO Sciences Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BioAdvance Capital (Conshohocken) | Venture Capital | Minority |
IO BiO Sciences FAQs
-
When was IO BiO Sciences founded?
IO BiO Sciences was founded in 2017.
-
Where is IO BiO Sciences headquartered?
IO BiO Sciences is headquartered in Doylestown, PA.
-
What is the size of IO BiO Sciences?
IO BiO Sciences has 4 total employees.
-
What industry is IO BiO Sciences in?
IO BiO Sciences’s primary industry is Drug Discovery.
-
Is IO BiO Sciences a private or public company?
IO BiO Sciences is a Private company.
-
What is IO BiO Sciences’s current revenue?
The current revenue for IO BiO Sciences is .
-
How much funding has IO BiO Sciences raised over time?
IO BiO Sciences has raised $3M.
-
Who are IO BiO Sciences’s investors?
BioAdvance Capital (Conshohocken) has invested in IO BiO Sciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
